Search

Pipemidic acid

Pipemidic acid is a quinolone antibacterial agent with activity against various gram-positive and gram-negative bacteria.

Benzoyl peroxide

[A234059,A234064,A234069] Benzoyl peroxide, in combination with erythromycin, was granted FDA approval on 26 October 1984.[L33264] … Benzoyl peroxide is a commonly used drug in topical treatments for acne.

Carbamide peroxide

of this ingredient as an oral wound healing agent [L1976]. … The FDA considers carbamide peroxide to be safe in oral mucosal injury drug products as an oral wound healing agent, although there is insufficient data to establish general recognition of the effectiveness

Losartan

[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423] … Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.

Nabumetone

[A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract. … Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568]

Platelet Activating Factor

Eszopiclone

Eszopiclone was initially approved by the FDA in 2004.[L6769]

Loratadine

[A176435] A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.

Clodronic acid

[A203111] Clodronic acid is not FDA approved, but is approved in Canada.[L13910] … [A1923] clodronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate [zoledronic acid], [ibandronic acid], [minodronic acid], and [risedronic acid]

Triazolam

Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. … Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.